Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.16% | -3.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.24% | 1.53% | |||
| Operating Income | -6.24% | -1.53% | |||
| Income Before Tax | -7.32% | -0.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.32% | -0.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.32% | -0.83% | |||
| EBIT | -6.24% | -1.53% | |||
| EBITDA | -6.23% | -1.53% | |||
| EPS Basic | -7.20% | 6.14% | |||
| Normalized Basic EPS | -7.22% | 6.15% | |||
| EPS Diluted | -7.20% | 6.14% | |||
| Normalized Diluted EPS | -7.22% | 6.15% | |||
| Average Basic Shares Outstanding | 0.10% | 7.43% | |||
| Average Diluted Shares Outstanding | 0.10% | 7.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||